This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Morphic Holding 관리

관리 기준 확인 3/4

Morphic Holding's CEO는 Praveen Tipirneni, Jul2015 에 임명되었습니다 의 임기는 9.08 년입니다. 총 연간 보상은 $ 8.91M, 6.9% 로 구성됩니다. 6.9% 급여 및 93.1% 보너스(회사 주식 및 옵션 포함). 는 € 34.49M 가치에 해당하는 회사 주식의 1.31% 직접 소유합니다. 34.49M. 경영진과 이사회의 평균 재임 기간은 각각 3.3 년과 7.2 년입니다.

주요 정보

Praveen Tipirneni

최고 경영자

US$8.9m

총 보상

CEO 급여 비율	6.9%
CEO 임기	9.1yrs
CEO 소유권	1.3%
경영진 평균 재임 기간	3.3yrs
이사회 평균 재임 기간	7.2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Praveen Tipirneni 의 보수는 Morphic Holding 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$180m
Mar 31 2024	n/a	n/a	-US$161m
Dec 31 2023	US$9m	US$614k	-US$152m
Sep 30 2023	n/a	n/a	-US$136m
Jun 30 2023	n/a	n/a	-US$130m
Mar 31 2023	n/a	n/a	-US$64m
Dec 31 2022	US$11m	US$602k	-US$59m
Sep 30 2022	n/a	n/a	-US$56m
Jun 30 2022	n/a	n/a	-US$51m
Mar 31 2022	n/a	n/a	-US$106m
Dec 31 2021	US$5m	US$579k	-US$96m
Sep 30 2021	n/a	n/a	-US$92m
Jun 30 2021	n/a	n/a	-US$61m
Mar 31 2021	n/a	n/a	-US$50m
Dec 31 2020	US$4m	US$559k	-US$45m
Sep 30 2020	n/a	n/a	-US$47m
Jun 30 2020	n/a	n/a	-US$61m
Mar 31 2020	n/a	n/a	-US$55m
Dec 31 2019	US$788k	US$498k	-US$43m
Sep 30 2019	n/a	n/a	-US$29m
Jun 30 2019	n/a	n/a	-US$27m
Mar 31 2019	n/a	n/a	-US$24m
Dec 31 2018	US$2m	US$402k	-US$24m

보상 대 시장: Praveen 의 총 보상 ($USD 8.91M )은 German 시장( $USD 1.53M ).

보상과 수익: Praveen 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Praveen Tipirneni (56 yo)

9.1yrs

테뉴어

US$8,907,684

보상

Dr. Praveen P. Tipirneni, M.D., M.B.A., has been Independent Director at Tectonic Therapeutic, Inc. He serves as an Independent Director at Panacea Acquisition Corp. II since April 6, 2021. He serves as Ch...

리더십 팀

이름	위치	테뉴어	보상	소유권
Praveen Tipirneni	CEO, MD & Director	9.1yrs	US$8.91m	1.31% $ 34.1m
Bruce Rogers	President	2.3yrs	US$4.88m	0.30% $ 7.8m
Timothy Springer	Founder	10yrs	US$539.99k	15.2% $ 395.7m
Marc Schegerin	CFO & COO	4.3yrs	US$4.65m	0.075% $ 2.0m
Robert Farrell	Senior VP of Finance & Chief Accounting Officer	4.6yrs	US$4.03m	0.023% $ 610.8k
Blaise Lippa	Chief Scientific Officer	2.3yrs	데이터 없음	데이터 없음
William DeVaul	General Counsel & Secretary	5.5yrs	US$2.24m	0.039% $ 1.0m
Aaron Pelta	Senior Vice President of Business & Corporate Development	2.3yrs	데이터 없음	데이터 없음
Joanne Gibbons	Senior Vice President of Regulatory Affairs	2.3yrs	데이터 없음	데이터 없음
Simon Cooper	Chief Medical Officer	less than a year	데이터 없음	데이터 없음

3.3yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: 31Y 의 관리팀은 경험 ( 3.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Praveen Tipirneni	CEO, MD & Director	9.1yrs	US$8.91m	1.31% $ 34.1m
Timothy Springer	Founder	9.2yrs	US$539.99k	15.2% $ 395.7m
Norbert Bischofberger	Independent Director	5.2yrs	US$545.74k	0% $ 0
Joseph Slattery	Independent Director	5.3yrs	US$560.74k	0.018% $ 469.9k
Martin Edwards	Independent Director	3.7yrs	US$547.49k	0.0047% $ 123.1k
Gustav Christensen	Independent Chairman	8.6yrs	US$586.49k	0.20% $ 5.2m
Amir Nashat	Independent Director	7.2yrs	US$544.99k	0.00029% $ 7.6k
Scott L. Friedman	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Ulrich von Andrian-Werburg	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Shelia Violette	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Albert Robichaud	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Yury Popov	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

7.2yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: 31Y 의 이사회는 경험(평균 재직 기간 7 년)으로 간주됩니다.

This company listing is no longer active

Morphic Holding 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Morphic Holding, Inc., Annual General Meeting, Jun 04, 2024

Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer

Insufficient new directors

Morphic Holding, Inc. Announces Chief Executive Officer Changes

Morphic Holdings Inc. Announces Chief Executive Officer, Praveen Tipirneni Suffered an Emergent Medical Event and Taking Medical Leave of Absence

Morphic Therapeutic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

Recent updates

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

New major risk - Share price stability

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Morphic Holding, Inc., Annual General Meeting, Jun 04, 2024

Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer

Full year 2023 earnings released: US$3.59 loss per share (vs US$1.55 loss in FY 2022)

Insufficient new directors

Morphic Holding, Inc. Announces Chief Executive Officer Changes

Third quarter 2023 earnings released: US$0.73 loss per share (vs US$0.78 loss in 3Q 2022)

Morphic Holdings Inc. Announces Chief Executive Officer, Praveen Tipirneni Suffered an Emergent Medical Event and Taking Medical Leave of Absence

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$0.70 profit in 2Q 2022)

First quarter 2023 earnings released: US$0.90 loss per share (vs US$0.85 loss in 1Q 2022)

Full year 2022 earnings released: US$1.55 loss per share (vs US$2.67 loss in FY 2021)

Morphic Holding, Inc. announced that it expects to receive $29.999954 million in funding

Morphic Therapeutic AnnouncesInitiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis

Third quarter 2022 earnings released: US$0.78 loss per share (vs US$0.69 loss in 3Q 2021)

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022

Second quarter 2022 earnings released: EPS: US$0.70 (vs US$0.77 loss in 2Q 2021)

Morphic Therapeutic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

Morphic Holding, Inc. Announces Management Appointments

First quarter 2022 earnings released: US$0.85 loss per share (vs US$0.64 loss in 1Q 2021)

Morphic Holding, Inc., Annual General Meeting, Jun 08, 2022

Morphic Therapeutic Announces Management Appointments

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Morphic Holding, Inc. Announces Retirement of Dr. Nilesh Kumar from the Board and Resign as Member of the Board and the Audit and Nominating and Governance Committees

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.17 profit in 3Q 2020)

Founder recently bought €3.6m worth of stock

Second quarter 2021 earnings released: US$0.77 loss per share (vs US$0.52 loss in 2Q 2020)

Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell 3000E Index

Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 At ECCO'21 Virtual Congress

Founder recently bought €8.7m worth of stock

Independent Director has left the company

First quarter 2021 earnings released: US$0.64 loss per share (vs US$0.56 loss in 1Q 2020)

Morphic Announces Clinical Results Update

Independent Director recently bought €59k worth of stock

Full year 2020 earnings released: US$1.47 loss per share (vs US$2.69 loss in FY 2019)

Revenue misses expectations

Morphic Holding, Inc. Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057

New 90-day high: €68.50

New 90-day high: €28.20

Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program

New 90-day high: €27.20

Morphic Holding, Inc. Appoints Martin Edwards to Serve on the Board as A Class II Director

New 90-day high: €25.60

Third quarter 2020 earnings released: EPS US$0.17

Revenue beats expectations

Morphic Announces Presentation of New Data Supporting Development of MORF-057 at UEG Week Virtual 2020

Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of MORF-057

Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell 3000 Value Index

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령